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Abstract
Background—Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV)
alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)–sparing benefits, low
pill burden, once-daily dosage, and safety.
Methods—Subjects with virologic suppression after ≥48 weeks of initial antiretroviral therapy with
2 NRTIs and a protease inhibitor (PI) were enrolled. Subjects switched to ATV/RTV at entry and
discontinued NRTIs after 6 weeks. The primary end point was time to virologic failure (confirmed
HIV-1 RNA level ≥200 copies/mL). Drug resistance at virologic failure was evaluated by standard
genotyping and single-genome sequencing (SGS). Residual viremia (1.1– 49 copies/mL) was
measured by single-copy assay.
Results—Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience
virologic failure by 48 weeks after simplification. Residual viremia did not change significantly after
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NRTI discontinuation among those without virologic failure but did increase 4 –12 weeks before
confirmed virologic failure. No major PI-resistance mutations were identified at virologic failure by
standard genotyping or SGS.
Conclusions—In this pilot study, simplified maintenance therapy with ATV/RTV alone
maintained viral suppression in most subjects through 48 weeks. PI resistance was not detected
among subjects experiencing virologic failure. Larger, randomized trials are warranted to further
define the efficacy and safety of this strategy.
Combination therapy with at least 3 antiretroviral agents is the current standard of care for
HIV-1 infection [1]; such therapy is maintained indefinitely in the absence of compelling
reasons for discontinuation. The long-term toxicities, cost, and difficulty of sustained
adherence to combination therapy have prompted investigation of simplified maintenance
regimens. A series of small pilot studies [2–4] and randomized clinical trials [5–7] suggest that
ritonavir (RTV)– boosted protease inhibitors (PIs) alone without other antiretroviral
medications hold promise for such a strategy. RTV-boosted atazanavir (ATV/RTV) is an
attractive option given its once-daily dosage, tolerability, and less-disadvantageous effects on
lipids [8,9].
AIDS Clinical Trials Group (ACTG) protocol 5201 was a prospective, open-label, single-arm
pilot trial of simplified maintenance therapy with ATV/RTV alone after sustained virologic
suppression. The primary analysis was published previously [10]: 31 (91%) of 34 subjects
maintained virologic suppression through 24 weeks after simplification. The present article
reports the final 48-week results for the trial and the results of more-sensitive assays for drug
resistance and residual viremia (HIV-1 RNA level) <50 copies/mL.
METHODS
The general methods for this study have been reported in detail elsewhere [10] and are
summarized here.
Trial design: open-label, prospective, single-arm pilot trial of regimen simplification to ATV/
RTV alone after sustained virologic suppression
Institutional review board approval was obtained at each of the 12 participating clinical sites.
All subjects provided written informed consent, and the human-experimentation guidelines of
the US Department of Health and Human Services were followed in the conduct of this
research. The primary objective was to evaluate the risk of virologic failure, defined as 2
consecutive HIV-1 RNA measurements ≥200 copies/mL after simplification to ATV/RTV
alone. Secondary objectives included safety and tolerability, detection of PI resistance–
associated mutations at virologic failure, changes in residual plasma HIV-1 RNA level, lipid
levels and CD4 cell counts, the relationship between plasma ATV concentrations and self-
reported adherence or virologic outcomes. This protocol was registered at ClinicalTrials.gov
(NCT00084019).
Eligibility criteria
Eligible subjects were aged 18 years or older, were receiving their first antiretroviral therapy
regimen (defined as at least 2 nucleoside reverse-transcriptase inhibitors [NRTIs] plus at least
1 PI for at least 48 weeks before entry), had a CD4 cell count >250 cells/μL, and had a plasma
HIV-1 RNA level <50 copies/mL for at least 48 weeks before entry. Subjects were excluded
if they had received nonnucleoside reverse-transcriptase inhibitors previously, had a history
of documented PI resistance, or were positive for hepatitis B surface antigen (because NRTIs
may have been needed for the treatment of hepatitis B).
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At entry, subjects discontinued their current PI and began taking ATV (300 mg daily) with
RTV (100 mg daily). Subjects who had treatment-limiting toxicities or a detectable plasma
HIV-1 RNA level 3 weeks after entry were discontinued from the study. Otherwise, subjects
discontinued their NRTIs 6 weeks after entry and simplified therapy to ATV/RTV alone.
Subjects were followed up for 48 weeks after simplification.
Study follow-up
Subjects had monthly follow-up visits for clinical assessments and plasma HIV-1 RNA
measurements. Plasma samples for ATV concentrations were collected 12–24 h after the last
dose of ATV. ATV concentrations were measured using previously reported methods [10].
The lower limit of detection for the high-performance liquid chromatography method used to
quantify ATV concentrations was 20 ng/mL. Adherence was also measured using the ACTG
self-report questionnaire [11].
Virologic analyses
For resistance testing, plasma samples with an HIV-1 RNA level >500 copies/mL from subjects
with protocol-defined virologic failure and from 1 subject with an HIV-1 RNA level >500
copies/mL at the final study visit were analyzed using both standard genotyping (ViroSeq;
version 2.6; ABI) and single-genome sequencing (SGS). For SGS analyses, we sought to obtain
45 or more sequences per sample to have 90% power to detect a resistant variant comprising
5% of the viral population. SGS analyses were performed as described elsewhere [12]. All 297
nt of the protease gene were sequenced by the dideoxyterminator method (ABI). Sequences
were analyzed for protease-resistance mutations by means of the Stanford Drug Resistance
Database and the International AIDS Society–USA drug-resistance mutation list [13,14].
For residual viremia, plasma samples from 13 study subjects were analyzed using a single-
copy assay (SCA) with a detection limit of 1.1 copies/mL, as reported elsewhere [15]. This
included 8 subjects without virologic failure, 4 with virologic failure, and 1 with an HIV-1
RNA level >200 copies/mL at the last study visit. All were known to have HIV-1 RNA that
could be amplified efficiently by SCA (10 from participation in another clinical trial with
pretherapy [16] and 3 subjects with virologic rebound).
Statistical analyses
The primary end point was time to virologic failure, defined as 2 consecutive plasma HIV-1
RNA measurements ≥200 copies/mL. The study was designed with 85% power to detect a
difference between week 24 success rates of 75% with ATV/RTV alone versus a nominal rate
of 90%, assuming an 8% dropout rate. The Kaplan-Meier method was used to estimate the
distribution of the time from simplification (i.e., discontinuation of NRTIs) to virologic failure.
The censoring time was defined as the time from simplification to the last HIV-1 RNA
measurement. Subjects who left the study before simplification were excluded from this
analysis. Greenwood’s variance was used to estimate the lower 90% 1-sided confidence
interval (CI) limit for the probability of virologic success at 48 weeks after simplification. A
relaxed type I error of 0.1 was chosen for the primary end point because this was a pilot study.
All other CIs and P values were 2-sided.
HIV-1 RNA levels for subjects analyzed by SCA for residual viremia were compared by
descriptive and nonparametric analyses. For independent groups, the Wilcoxon-Mann-
Whitney U test (for continuous outcomes) and Fisher’s exact test (for binary outcomes) were
used; for comparing continuous outcomes between time points within subjects, the Wilcoxon
signed-rank exact test was used.
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Baseline characteristics and subject disposition
Thirty-six subjects were enrolled from September 2004 through April 2005. Baseline
characteristics are shown in table 1. Two subjects discontinued the study before simplifying
to ATV/RTV alone: one because of scleral icterus and the other because of a plasma HIV-1
RNA level of 50 copies/mL. Thirty-four subjects simplified therapy to ATV/RTV alone. Two
of the 34 subjects discontinued the study follow-up before 48 weeks because of an inability to
attend study visits: one was followed up for 8 weeks after simplification to ATV/RTV alone
and the other for 36 weeks.
Primary end point
Four subjects had confirmed virologic failure while receiving ATV/RTV alone, at 12, 12, 20,
and 28 study weeks after simplification. The Kaplan-Meier estimate of the probability of
virologic success at week 48 was 0.88 (lower 90% 1-sided CI limit, 0.81). Plasma HIV-1 RNA
levels at the time of virologic failure were 4730, 1285, 28,397, and 626 copies/mL, respectively.
In one other subject, the plasma HIV-1 RNA level was 508 copies/mL at the final study visit.
Because this value was not confirmed, criteria were not met for protocol-defined virologic
failure. A sensitivity analysis including this subject decreased the probability of virologic
success to 0.84 (lower 90% 1-sided CI limit, 0.76). When a confirmed HIV-1 RNA level ≥50
copies/mL was used as a more-stringent definition of virologic failure, the probability of
virologic success was 0.82 (lower 90% 1-sided CI limit, 0.73).
One subject with virologic failure at week 12 continued to receive ATV/RTV alone. Two other
subjects continued to receive ATV/RTV and restarted NRTIs (tenofovir/emtricitabine). One
subject discontinued ATV/RTV and initiated lopinavir (LPV)/RTV with tenofovir/
emtricitabine. All 4 subjects subsequently achieved a plasma HIV-1 RNA level <50 copies/
mL, but 2 of the 4 subjects had an intermittently detectable plasma HIV-1 RNA level during
follow-up.
For the 30 subjects without virologic failure, plasma HIV-1 RNA levels over the course of the
study were below the limit of detection (<50 copies/mL) in 304 (95%) of 321 samples collected
during receipt of ATV/RTV alone. The 17 samples with detectable HIV-1 RNA levels were
distributed among 9 subjects: 12 samples had 50 –199 copies/mL, and 5 had unconfirmed
measurements ≥200 copies/mL.
Drug-resistance analysis
No major PI-resistance mutations were detected by standard population genotyping analyses
for the 4 subjects with confirmed virologic failure or for the subject with viremia >200 copies/
mL at the last study visit. SGS analysis was performed on failure samples from all 5 of these
subjects. An average of 47 (range, 43–53) genomes per sample was analyzed to determine the
presence of polymorphisms and resistance mutations in protease. No major PI mutations were
identified in any of the 236 single-genome sequences analyzed, but several minor PI mutations
and polymorphisms were identified. For 2 subjects, I64V was detected in 2 of 100 sequences
combined, and G73S was detected in 2 of 90 sequences from 2 other participants. None of the
minor mutations or polymorphisms identified by SGS was predicted to alter susceptibility to
ATV.
Residual viremia
Plasma samples from 13 subjects were tested by SCA to determine the effects of regimen
simplification on residual viremia (table 2). The median level of residual viremia in subjects
without virologic failure (n = 8) was <1.1 copies/mL (interquartile range, <1.1 to 2.4 copies/
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mL). There was no statistically significant difference in median residual viremia between study
entry and after 48 weeks among subjects without virologic failure (P = .219, Wilcoxon signed-
rank exact test). By contrast, the level of residual viremia increased in all 5 subjects with
virologic failure or rebound 4 –12 weeks before HIV-1 RNA was detectable (>50 copies/mL),
as determined by standard assay (table 2).
Pharmacokinetic/adherence analysis
Thirty-one (91%) of 34 subjects had detectable ATV concentrations at every measurement
while receiving ATV/RTV alone. Among the 3 subjects with at least 1 ATV concentration
below the limit of detection, 2 (67%) developed virologic failure, whereas, among the 31
subjects with detectable ATV at every measurement, two (6%) developed virologic failure
(P = .03, Fisher’s exact test). The median ATV level among subjects with virologic failure was
380 ng/mL, compared with 660 ng/mL among those without virologic failure (P = .18,
Wilcoxon rank-sum test). Changes in ATV concentrations did not correlate with changes in
residual viremia among subjects with virologic failure (data not shown).
Adverse events
Seventeen of 34 subjects had grade 3 or 4 increases in total bilirubin level. One grade 3 elevation
in lipase level and 1 grade 3 elevation in phosphorus level were observed. No AIDS-defining
illnesses occurred. CD4 cell counts did not change appreciably during the course of the study.
Overall, lipid levels did not change significantly from the time of initiating ATV/RTV plus 2
NRTIs to 48 weeks after discontinuing NRTIs.
DISCUSSION
The present pilot study suggests that simplified maintenance therapy with ATV/RTV alone
can maintain virologic suppression in most patients with prior virologic suppression who were
receiving a PI-based regimen with 2 NRTIs. Moreover, major PI-resistance mutations did not
develop in the 4 subjects with virologic failure or in the 1 subject with an HIV-1 RNA level
>200 copies/mL at the final study visit, as determined by either standard population genotyping
or the more-sensitive method of SGS. Subjects with virologic failure were more likely to have
study visits with undetectable ATV concentrations. This strongly suggests that suboptimal
adherence was an important factor in the development of virologic failure.
Among subjects without virologic failure, 95% of plasma HIV-1 RNA measurements were
<50 copies/mL. This is similar to what was observed in ACTG 5095, a recent large, double-
blind, placebo-controlled trial of 3 different antiretroviral regimens for initial treatment of HIV-
infected subjects [17,18]. Among subjects in ACTG 5095 without virologic failure (same
definition as the present study), 93% of HIV-1 RNA measurements obtained during the second
year of antiretroviral therapy were <50 copies/mL (H. Ribaudo, personal communication).
In the present study, we monitored residual viremia <50 copies/mL by SCA in longitudinal
samples before and after simplification of therapy in a subset of study subjects with or without
virologic failure. The median level of residual viremia did not increase significantly after
simplification of therapy among subjects without virologic failure, whereas increases in
residual viremia were detectable by SCA 4 –12 weeks before rebound was evident by a standard
HIV-1 RNA assay. Although the number of observations is small, the findings are consistent
with published data from a prior pilot study of maintenance therapy with LPV/RTV alone
[19] and suggest that more-sensitive HIV-1 RNA assays can be used to identify impending
virologic failure with sufficient lead time to allow therapeutic intervention (e.g., adherence
counseling and reinitiation of NRTIs). As noted above, monitoring of drug levels may also
identify those at risk for virologic failure.
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The present study adds to a growing body of data that simplified maintenance therapy with a
boosted PI alone is effective in maintaining virologic control after initial suppression with a
3-drug regimen. Other studies of simplification have evaluated maintenance regimens with
ATV, indinavir, and LPV, each boosted with RTV [2–7,20]. In these studies, similar
proportions of subjects maintained virologic suppression as that observed in the present study.
It should be noted, however, that one study of ATV/RTV alone was stopped early because it
reached predefined stopping rules for suboptimal efficacy (5 of 15 subjects with virologic
failure, defined as confirmed plasma HIV-1 RNA level >20 copies/mL) [20]. However, that
study differed from ours in that patients were allowed to continue medications with known
adverse pharmacologic interactions with ATV and used an HIV-1 RNA level of >20 copies/
mL to define virologic failure.
Concern exists about increased risk of virologic failure, possibly associated with the
development of PI resistance, after simplification to ATV/RTV or another RTV-boosted PI
alone. This has been an infrequent event, noted in <2% of subjects in trials of simplified
maintenance therapy [2–7,20].
The present study has several limitations. It was a pilot study and did not have a randomized
control group. The population was highly selected in that they had received antiretroviral
therapy for a median of 6.8 years without a prior history of virologic failure. The follow-up
performed in this study was more frequent than would be done in clinical practice. As a result,
the time spent with ongoing viremia for subjects with virologic failure was minimized.
Development of drug resistance may occur with longer periods of viremia. The residual viremia
testing was performed on a nonrandom sample of subjects without virologic failure, which
could have introduced bias. However, this selection of subjects with pretherapy samples
available ensured that undetectable HIV-1 RNA by the SCA was due to viral suppression rather
than inefficient polymerase chain reaction amplification.
Simplified maintenance therapy challenges the current paradigms for treatment of HIV-1
infection and should be evaluated carefully. The risk of viral rebound during receipt of ATV/
RTV or other RTV-boosted PIs alone may be greater than that during continuation of a standard
3-drug regimen. This would have long-term adverse consequences only if PI resistance
develops or if resuppression of viremia is not achieved after reinitiating NRTIs, which has been
infrequent and was not observed in our study. A higher risk of viral rebound may be balanced
by the possibility of durable simplified therapy and decreased exposure to other drug classes.
Indeed, Schackman et al. [21] have modeled the long-term outcomes of ATV/RTV
maintenance therapy, compared with those of a standard 3-drug regimen, and found that the
simplified strategy provided cost and survival advantages if the frequency of PI resistance and
cross-resistance was low. However, this strategy cannot be recommended for clinical practice
until large, adequately powered randomized trials are performed.
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 Asian/Pacific Islander 1 (3)
Age category
 20–29 years 2 (6)
 30–39 years 16 (44)
 40–49 years 13 (36)
 50 years and above 5 (14)
Time receiving ART, median (IQR), years 6.8 (4.2–7.0)
CD4 cell count, median (IQR), cells/μL 616 (443–756)







NOTE. Data are no. (%) of subjects, unless otherwise specified. ART, antiretroviral therapy; IQR, interquartile range; PI, protease inhibitor.
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